NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Motilal Oswal Research Report: UltraTech Cement

Key Highlights

UltraTech Cement (UTCEM) has outpaced industry growth through organic expansion and strategic acquisitions, increasing its market share from 16% in FY14-15 to 28% in FY25 and 29% in 9MFY26.

Capacity Addition Plan

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

The company is executing a multi-phase capacity addition plan to raise domestic grey cement capacity to 235.4mtpa by FY28, up from the current 191.4mtpa. During FY23-25, UTCEM contributed 38% of the industry's capacity additions, and it is expected to add 28% of incremental industry capacity during FY26-28.

Integration and Cost Optimization

The integration of acquired assets (Kesoram and ICEM) is progressing well, with meaningful brand transition and operational restructuring underway. Cost-optimization initiatives are expected to deliver cumulative savings of INR300-350/t over the medium term, with INR86/t achieved in FY25 and a target of INR100/t in FY26E.

Outlook

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

We estimate a consolidated revenue/EBITDA/PAT CAGR of 12%/18%/22% over FY26-28, driven by 10% volume CAGR and 2pp OPM expansion to 21% by FY28. Profitability improvement and disciplined capex should lift the RoE/RoCE to 14%/13% by FY28.

Valuation

We value UTCEM at 19x FY28E EV/EBITDA to arrive at our target price of INR15,000. We reiterate a BUY recommendation.

Investor Takeaway

Investors may consider a long-term investment in UltraTech Cement.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.